Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients-Reference-Cited by-同舟云学术

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients

Published:2011-02-08 Issue:3 Volume:30 Page:1055-1064
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Fujiwara Yutaka,Kiyota Naomi,Chayahara Naoko,Suzuki Akiyuki,Umeyama Yoshiko,Mukohara Toru,Minami Hironobu

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://www.springerlink.com/index/pdf/10.1007/s10637-011-9637-1

Reference33 articles.

1. Kelly RJ, Rixe O (2010) Axitinib (AG-013736). Recent Results Cancer Res 184:33–44

2. Choueiri TK (2008) Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs 9:658–671

3. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O’Connor P, Shalinsky DR, Bender SL (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14:7272–7283. doi: 10.1158/1078-0432.CCR-08-0652

4. Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, McShane TM, Lu Y, Brasch RC, Hylton NM (2007) AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 25:319–327. doi: 10.1016/j.mri.2006.09.041

5. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8:975–984. doi: 10.1016/S1470-2045(07)70285-1

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune Checkpoint Inhibitor (Pembrolizumab)- and Tyrosine Kinase Inhibitor (Axitinib)-induced Hypothyroidism, Hypogonadism, Adrenal Insufficiency, and Dysglycemia in a Patient with Renal Cell Carcinoma;Bangladesh Journal of Endocrinology and Metabolism;2024-09-12

2. Influence of two anti-tumor drugs, pazopanib, and axitinib, on the development and thyroid-axis of zebrafish (Danio rerio) embryos/larvae;Frontiers in Endocrinology;2023-07-31

3. Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/ KEYNOTE ‐775;Cancer Science;2022-07-26

4. Systemic Treatments and Related Side Effects in Thyroid Cancer;Radionuclide Therapy;2022

5. Systemic Treatments and Related Side Effects in Liver Tumors;Radionuclide Therapy;2022